Literature DB >> 8968359

Arterial and venous cocaine plasma concentrations in humans: relationship to route of administration, cardiovascular effects and subjective effects.

S M Evans1, E J Cone, J E Henningfield.   

Abstract

Arterial plasma drug concentrations should be a strong predictor of resultant physiological and behavioral effects of smoked drugs. Nine healthy male volunteers, who were current users of smoked and i.v. cocaine, participated in a study directly comparing arterial and venous cocaine plasma concentrations after smoked and i.v. cocaine. Each volunteer was first tested under all dosing conditions without an arterial catheter (phase I), to determine whether subjects could tolerate each cocaine dose, before testing with an arterial catheter (phase II). Phase II consisted of two test days, each consisting of either four smoked-cocaine sessions (sham, 12.5, 25 and 50 mg) or four i.v. cocaine sessions (0, 8, 16 and 32 mg) in ascending order, spaced 90 min apart. For the two highest doses for each route, arterial and venous blood samples were taken simultaneously before drug administration, during drug administration and frequently after drug administration. At the same time, cardiovascular effects and subjective effects were measured. Arterial cocaine concentrations were substantially higher than venous cocaine concentrations after both routes of cocaine administration. After either smoked or i.v. cocaine, maximal arterial cocaine concentrations occurred within 15 sec, whereas maximal venous cocaine concentrations occurred within 4 min. The onset of cardiovascular and subjective effects was also rapid, and arterial cocaine concentrations tended to account for these effects to a greater extent than did venous cocaine concentrations. Even though arterial and venous cocaine concentrations were lower after smoked cocaine, compared with i.v. cocaine, the magnitudes of cardiovascular and subjective effects were similar, suggesting that smoked cocaine may produce a greater effect at similar concentrations. These findings do not support the hypothesis that the greater effects observed after smoking are a result of smoked cocaine reaching the brain faster than i.v. cocaine as measured by peripheral arterial plasma concentrations.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8968359

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  50 in total

Review 1.  Pharmacotherapeutics directed at deficiencies associated with cocaine dependence: focus on dopamine, norepinephrine and glutamate.

Authors:  Colin N Haile; James J Mahoney; Thomas F Newton; Richard De La Garza
Journal:  Pharmacol Ther       Date:  2012-01-31       Impact factor: 12.310

2.  Smoking produces rapid rise of [11C]nicotine in human brain.

Authors:  Marc S Berridge; Scott M Apana; Kenichi K Nagano; Catherine E Berridge; Gregory P Leisure; Mark V Boswell
Journal:  Psychopharmacology (Berl)       Date:  2010-03-16       Impact factor: 4.530

Review 3.  Translational neuroimaging: positron emission tomography studies of monoamine oxidase.

Authors:  Joanna S Fowler; Jean Logan; Nora D Volkow; Gene-Jack Wang
Journal:  Mol Imaging Biol       Date:  2005 Nov-Dec       Impact factor: 3.488

4.  Amelioration of the cardiovascular effects of cocaine in rhesus monkeys by a long-acting mutant form of cocaine esterase.

Authors:  Gregory T Collins; Kathy A Carey; Diwahar Narasimhan; Joseph Nichols; Aaron A Berlin; Nicholas W Lukacs; Roger K Sunahara; James H Woods; Mei-Chuan Ko
Journal:  Neuropsychopharmacology       Date:  2011-02-02       Impact factor: 7.853

Review 5.  Drugs, biogenic amine targets and the developing brain.

Authors:  Aliya L Frederick; Gregg D Stanwood
Journal:  Dev Neurosci       Date:  2009-04-17       Impact factor: 2.984

6.  Revisiting a physiologically based pharmacokinetic model for cocaine with a forensic scope.

Authors:  María Elena Bravo-Gómez; Laura Nayeli Camacho-García; Luz Alejandra Castillo-Alanís; Miguel Ángel Mendoza-Meléndez; Alejandra Quijano-Mateos
Journal:  Toxicol Res (Camb)       Date:  2019-03-13       Impact factor: 3.524

Review 7.  Pharmacokinetic-Pharmacodynamic (PKPD) Analysis with Drug Discrimination.

Authors:  S Stevens Negus; Matthew L Banks
Journal:  Curr Top Behav Neurosci       Date:  2018

Review 8.  Abuse liability assessment of tobacco products including potential reduced exposure products.

Authors:  Lawrence P Carter; Maxine L Stitzer; Jack E Henningfield; Rich J O'Connor; K Michael Cummings; Dorothy K Hatsukami
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-12       Impact factor: 4.254

Review 9.  Hormones, nicotine, and cocaine: clinical studies.

Authors:  Nancy K Mello
Journal:  Horm Behav       Date:  2009-10-14       Impact factor: 3.587

Review 10.  Prenatal exposure to drugs: effects on brain development and implications for policy and education.

Authors:  Barbara L Thompson; Pat Levitt; Gregg D Stanwood
Journal:  Nat Rev Neurosci       Date:  2009-03-11       Impact factor: 34.870

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.